Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

James Moren

Family Medicine Bellingham, WA Medical Doctor

NPI 1255388427 CMS profile 238430

220 Unity St, Bellingham, WA 98225

Open in the dashboard

General payments

$105,939

198 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, James Moren of Bellingham, WA is reported in the CMS Open Payments database as having received $105,939 across 198 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $114 1
2022 General $7,454 17
2021 General $34,549 53
2020 General $32,696 40
2019 General $31,127 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Moren
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to James Moren were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year James Moren Family Medicine median Middle half National median
2019 $31,127 $150 $41–$543 $163
2020 $32,696 $120 $32–$415 $114
2021 $34,549 $137 $35–$551 $132
2022 $7,454 $137 $37–$512 $149
2023 $114 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Teva Pharmaceuticals USA, Inc. $29,213 60 payments
  2. Amgen Inc. $24,683 38 payments
  3. AbbVie, Inc. $21,434 31 payments
  4. Allergan Inc. $13,761 20 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $6,232 12 payments
  6. Biohaven Pharmaceuticals, Inc. $5,946 11 payments
  7. Lundbeck LLC $4,302 11 payments
  8. Impel Pharmaceuticals Inc. $114 1 payment
  9. Novartis Pharmaceuticals Corporation $78 4 payments
  10. Avanos Medical $44 3 payments
  11. Other $132 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,648 48 payments
  2. Consulting Fee $9,710 14 payments
  3. Travel and Lodging $8,386 33 payments
  4. Food and Beverage $4,143 101 payments
  5. Education $53 2 payments
Products named General payments · program years 2019–2023
  1. AIMOVIG $24,761 42 payments
  2. UBRELVY Neuroscience $24,011 34 payments
  3. Ajovy Central Nervous System $14,968 46 payments
  4. AJOVY Central Nervous System $14,226 13 payments
  5. NURTEC ODT $12,178 23 payments
  6. UBRELVY Neuroscience $11,032 14 payments
  7. VYEPTI $4,302 11 payments
  8. BOTOX $117 1 payment
  9. Trudhesa $114 1 payment
  10. GENERATOR $44 3 payments
  11. Other $167 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

198 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record